AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AWT-020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AWT-020 overview

AWT-020 is under development for the treatment of NSCLC (non-small cell lung cancer), RCC (renal cell carcinoma), melanoma, colon carcinoma, breast cancer, urothelial carcinoma, sarcoma and hepatocellular carcinoma. It is a targeted fusion protein comprised of an anti-PD1 antibody linked to a potency optimized IL-2Na. It is being developed based on AccuKine and AccuBody platform and is administered through intravenous route.

Anwita Biosciences overview

Anwita Biosciences is an emerging biopharmaceutical company. The company is specialized in the discovery and development of optimized immuno-therapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering. Anwita Biosciences is headquartered in San Carlos, California, the US.

For a complete picture of AWT-020’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.